Cadila Healthcare gets approval for gLodosyn
This is a small product and not very significant for Cadila Healthcare.
Cadila Healthcare’s subsidiary Zydus Pharmaceuticals USA Inc., has received final approval for Carbidopa 25mg. This is a generic equivalent of Lodosyn 25mg tablets manufactured by Aton Pharma.
Carbidopa 25 mg, including its brand and generics had US sales of ~$32mn and most of which were generated by generics. Lupin also has approval for gLodosyn.
We believe that Cadila will be able to make $1-2mn from this product, and hence, not a significant product for the company.
Nse&Bse tips, Intraday tips is also the part of our advisory recommendations you can also know more if you are interested in Financial Trading to click here subscribe us free >>Bonaz Capital